6 completed, 2 recruiting, 1 enrolling by invitation. 9 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Recruiting 2, Enrolling by invitation 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Delusions: new trials by email Literature Review of Delusions trials Research Report on Delusions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis ML-007C-MA - Psychosis Associated With Alzheimer's Disease | Phase 2 | Enrolling by invitation | MapLight Therapeutics | 210 | 2026-03-25 | 2026-11-12 |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis ML-007C-MA, Placebo - Psychosis Associated With Alzheimer's Disease | Phase 2 | Recruiting | MapLight Therapeutics | 300 | 2025-08-15 | 2026-11-12 |
| ACP-204 in Adults With Alzheimer's Disease Psychosis ACP-204, Placebo - Alzheimer's Disease Psychosis | Phase 2 / Phase 3 | Recruiting | ACADIA Pharmaceuticals Inc. | 1074 | 2023-11-14 | 2026-11-05 |
| Treatment of Psychosis and Agitation in Alzheimer's Disease Lithium, Placebo - Alzheimer's Disease, Psychosis | Phase 2 | Completed | New York State Psychiatric Institute | 77 | 2014-06-01 | 2024-05-02 |
| Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Placebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses) - Schizophrenia Disorders | Phase 2 | Completed | Novartis Pharmaceuticals | 57 | 2010-05-01 | 2020-12-24 |
| Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia t-VNS verum, t-VNS placebo - Schizophrenia | Phase 2 | Completed | cerbomed GmbH | 20 | 2010-03-01 | 2012-09-12 |
| Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone ACP-103 - Schizophrenia | Phase 2 | Completed | ACADIA Pharmaceuticals Inc. | 400 | 2005-08-01 | 2007-03-22 |
| Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants Ethyl-eicosapentaenoic acid (EPA), Vitamins E + C, Etyl EPA (placebo) - Schizophrenia, Schizophreniform Disorders | Phase 2 / Phase 3 | Completed | University Hospital, Aker | 99 | 2001-09-01 | 2011-01-04 |
| Treating Behavioral Disturbances in Individuals With Dementia Citalopram, Risperidone - Dementia | Phase 2 | Completed | University of Pittsburgh | 137 | 2000-01-01 | 2014-03-10 |
Hallucinations (8) · Psychotic Disorders (6) · Alzheimer Disease (4) · Dementia (4) · Mental Disorders (4) · Schizophrenia (4) · Aggression (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Nervous System Diseases (2) · Neurocognitive Disorders (2) · Neurodegenerative Diseases (2) · Schizophrenia Spectrum and Other Psychotic Disorders (2) · Tauopathies (2)
Behavior (9) · Behavioral Symptoms (9) · Neurobehavioral Manifestations (8) · Neurologic Manifestations (8) · Pathological Conditions, Signs and Symptoms (8) · Perceptual Disorders (8) · Signs and Symptoms (8) · Nervous System Diseases (7) · Schizophrenia Spectrum and Other Psychotic Disorders (5) · Mental Disorders (4) · Neurocognitive Disorders (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Aberrant Motor Behavior in Dementia (2) · Dyskinesias (2)
3-(6-p-tolylpyridin-3-yloxy)-1-azabicyclo(2.2.2)octane (1) · Citalopram (1) · Lithium (1) · Lithium Carbonate (1) · Risperidone (1) · Single Person (1) · eicosapentaenoic acid ethyl ester (1) · pimavanserin (1)
ACADIA Pharmaceuticals Inc. (2) · MapLight Therapeutics (2) · New York State Psychiatric Institute (1) · Novartis Pharmaceuticals (1) · University Hospital, Aker (1) · University of Pittsburgh (1) · cerbomed GmbH (1)
United States (7) · Bulgaria (3) · France (3) · Brazil (2) · Chile (2) · Czechia (2) · Italy (2) · Serbia (2) · South Korea (2) · Argentina (1) · Canada (1) · Germany (1) · Hungary (1) · Mexico (1) · Norway (1)
Bruce G. Pollock, MD, PhD (1) · DP Devanand, MD (1) · Daniel van Kammen, MD, PhD (1)
PMID 20625270, PMID 29859917, PMID 34059401, PMID 37732619
2025 (1), R01AG047146 (1), R01MH059666 (1)